Vallari Shah

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

Ali Roghanian, Ingrid Teige, Linda Mårtensson et al. · Cancer Cell · 2015 · 133 citations · Full text

Pharmacy, Immunology, Oncology +14

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

Gordon Cook, Kara‐Louise Royle, Charlotte Pawlyn et al. · The Lancet Haematology · 2019 · 109 citations · Full text

Public Health, Biostatistics, Risk Assessment +13

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial

Charlotte Pawlyn, David A. Cairns, Martin Kaiser et al. · Leukemia · 2019 · 98 citations · Full text

Medicine, Geriatric Medicine, Oncology +15

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew Vaughan, Chisako Iriyama, Stephen A. Beers et al. · Blood · 2013 · 76 citations

Life Sciences, Cell Biology, Immunology +14

Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London

Beth Russell, Charlotte Moss, Vallari Shah et al. · British Journal of Cancer · 2021 · 59 citations · Full text

Medicine, Infectious Diseases, Oncology +15